文献速递乳腺癌

CTS5风险评分在高危ER阳性乳腺癌中高估晚期远处复发:TEAM与IDEAL试验验证

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
PubMed 文献 · J Clin Oncol · 2020-07-24

研究利用TEAM和IDEAL试验数据外部验证CTS5评分对5年后远处复发(DR)的区分度与校准度,并检验其预测延长内分泌治疗获益的能力。

要点

  • CTS5可区分低、中、高危组,但高危组预测复发率显著高于实际观察值。
  • 高危组10年DR风险显著高于低危组(HR 5.7,95%CI 3.6-8.8)。
  • CTS5不能预测延长辅助内分泌治疗的获益,数值解读需谨慎。

核心结论

  • CTS5评分能区分风险类别但高估高危患者晚期远处复发风险,当前形式下数值风险应谨慎解读。

研究设计与样本

  • 外部验证研究,使用TEAM试验5895例和IDEAL试验1591例患者数据评估区分度与校准度。
  • IDEAL试验数据用于检验CTS5对延长内分泌治疗获益的预测价值。

主要发现

  • 10年时高危和中危组DR显著多于低危组(HR 5.7,95%CI 3.6-8.8;HR 2.8,95%CI 1.7-4.4)。
  • 低危和中危组CTS5预测DR率高于观察值但无统计学显著性。
  • CTS5对延长辅助内分泌治疗 duration 无预测作用。

关键数值与推荐

  • CTS5将5年无病患者分为低、中、高危,计算5-10年DR绝对风险。

临床怎么用

  • 临床使用CTS5 calculator评估晚期复发风险时,尤其高危患者应谨慎解读数值风险。
  • 不应依据CTS5评分单独决定是否延长辅助内分泌治疗。

局限性

  • 基于TEAM和IDEAL试验人群的外部验证,结果可能受入组特征影响。
  • 低危和中危组的校准偏差未达统计学显著性,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Most distant recurrences (DRs) in women with hormone receptor-positive breast cancer occur after 5 years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) estimates DRs after 5 years of adjuvant endocrine therapy (AET). The aim of this study was to externally validate the CTS5 as a prognostic/predictive tool. METHODS: The CTS5 categorizes patients who have been disease free for 5 years into low, intermediate, and high risk and calculates an absolute risk for developing DRs between 5 and 10 years. Discrimination and calibration were assessed using data from the TEAM and IDEAL trials. The predictive value of the CTS5 was tested with data from the IDEAL trial. RESULTS: A total of 5,895 patients from the TEAM trial and 1,591 patients from the IDEAL trial were included. When assessing the CTS5 discrimination, significantly more DRs were found at 10 years after diagnosis in the CTS5 high- and intermediate-risk groups than in the low-risk group (hazard ratio, 5.7 [95% CI, 3.6 to 8.8] and 2.8 [95% CI, 1.7 to 4.4], respectively). In low- and intermediate-risk patients, the CTS5-predicted DR rates were higher, although not statistically significantly so, than observed rates. However, in high-risk patients, the CTS5-predicted DR rates were significantly higher than observed rates (29% v 19%, respectively; P < .001). The CTS5 was not predictive for extended AET duration. CONCLUSION: The CTS5 score as applied to patients treated in the TEAM and IDEAL cohorts discriminates between risk categories but overestimates the risk of late DRs in high-risk patients. Therefore, the numerical risk assessment from the CTS5 calculator in its current form should be interpreted with caution when used in daily clinical practice, particularly in high-risk patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, et al. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. J Clin Oncol. 2020. PMID: 32706636. doi:10.1200/JCO.19.02427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。